Skip to content

Clinical trials

Diabetes Mellitus trials in Germany with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus Phase: Not applicable Country / region: Germany Clear all

100 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20044
20051
20094
20105
20111
20125
20135
20146
20158
20168
20177
20185
20196
20206
20214
20226
20238
20244
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed79
Unknown status6
Recruiting6
Terminated4
Withdrawn2
Suspended1
Not yet recruiting1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institut fur Diabetes Karlsburg GmbH14
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm12
Forschungsinstitut der Diabetes Akademie Mergentheim7
RSP Systems A/S5
EyeSense GmbH4
University Hospital Tuebingen4
German Institute of Human Nutrition3
Medtronic MiniMed, Inc.3
Medtronic Vascular3
Profil Institut für Stoffwechselforschung GmbH3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus100
Diabetes Mellitus, Type 210
Hypertension5
Cardiovascular Diseases4
Diabetes Mellitus, Type 14
Insulin Resistance4
Metabolic Syndrome4
Renal Insufficiency, Chronic4
Vascular Diseases4
Obesity3

Trials

Showing 1 to 25 of 100. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.